Table 3.

Patient CiTAS scores depending on the disease and treatment characteristics

Disease and treatment characteristics	n (%)	Decline in Basic Taste Mean±SD	Phantogeusia and Parageusia Mean±SD	Discomfort Mean±SD	General taste alterations Mean±SD
Diagnosis
Lymphoma	20 (10.9)	1.7±0.9	2.7±1.0	2.7±1.0	2.6±1.1
Multiple myeloma	19 (10.3)	1.4±0.3	2.1±0.8	2.6±1.1	2.4±0.9
Breast cancer	46 (25.0)	1.8±1.0	2.5±1.0	2.7±1.3	2.6±1.0
Lung cancer	25 (13.6)	1.9±1.1	2.8±0.9	2.9±1.2	2.9±1.1
Colorectal cancer	42 (22.8)	1.6±0.9	2.8±0.8	2.4±1.1	2.8±1.0
Over cancer	13 (7.1)	1.6±0.9	3.1±1.1	2.9±1.4	2.9±1.1
Pancreatic cancer	6 (3.3)	1.7±1.2	2.7±0.8	3.2±1.7	3.2±1.0
Other*	13 (7)	2.1±1.4	2.5±0.9	2.9±1.4	2.9±1.2
		H=2.6 p=0.919	H=10.9 p=0.143	H=3.9 p=0.784	H=5.4 p=0.605
Clinical Stage
I	20 (10.9)	1.5±0.7	2.7±0.9	2.6±1.3	2.8±1.2
II	69 (37.5)	1.6±0.9	2.6±0.9	2.5±1.2	2.8±1.0
III	53 (28.8)	1.8±1.1	2.6±1.0	2.9±1.1	2.6±1.0
IV	42 (22.8)	2.0±1.1	2.8±0.9	2.9±1.4	2.9±1.1
		H=3.26 p=0.352	H=1.28 p=0.732	H=3.95 p=0.265	H=2.65 p=0.448
Treatment Protocol
Paclitaxel+herceptin	29	1.7±0.9	2.3±0.8	2.9±1.2	2.6±1.0
Fluorouracil+calcium folinate+irinotecan. bevacizumab	25	1.7±1.1	2.9±0.8	2.5±1.2	3.0±1.1
Paclitaxel	19	1.8±1.1	2.6±1.1	2.6±1.4	2.7±0.9
Gemcitabine+cisplatin	26	2.2±1.3	2.8±1.0	2.9±1.4	2.9±1.2
Carboplatin+paclitaxel	15	1.9±1.0	2.6±0.8	2.8±1.4	2.6±1.2
Cyclophosphamide+bortezomib+dexamethasone	11	1.4±0.4	2.0±0.8	2.7±1.2	2.2±0.8
Fluorouracil+calcium folinate+oxaliplatin	13	1.2±0.4	2.5±0.9	2.4±1.2	2.6±1.1
Rituximab+Cyclophosphamide+doxorubicin+vincristine+prednol	12	1.7±0.9	2.3±0.9	2.6±1.2	2.5±1.0
Doxorubicin+bleomycin+vinblastine+dacarbazine	8	1.7±0.9	3.2±1.2	3.3±0.8	3.2±1.2
Other*	26	1.7±1.0	2.8±1.0	2.6±1.2	3.0±1.0
		H=5.103 p=0.825	H=12.737 p=0.174	H=5.782 p=0.761	H=8.957 p=0.441